OmniaBio has access to cutting-edge, end-to-end technologies through industry partnerships with Cytiva and CCRM, ensuring ongoing access to state-of-the-art advances for autologous, allogeneic and viral vector platforms. OmniaBio will complete CCRM’s continuum of process development and manufacturing capabilities, enabling the execution of work for Phase III clinical trials and commercial-scale manufacturing, building on the early-stage work that takes place at CCRM’s Centre for Cell and Vector Production (CCVP) located at the MaRS Centre in Toronto’s Discovery District.

Find out more about our facilities by project stage



OmniaBio will be the anchor tenant in a biomanufacturing centre of excellence at McMaster Innovation Park in Hamilton, Ontario. The  OmniaBio biomanufacturing sites are opening in a scaled launch between 2024 and 2026, and will total 400,000 sq ft of space adding to the existing 40,000 sq ft of process development and cGMP space at the Toronto site. It will support therapy developers in Canada and internationally by offering both full-service and hoteling options, providing access to cutting-edge allogeneic, autologous and viral vector manufacturing platforms. Facility benefits include:

  • Flexible Operations: Ranging from conventional full-service to customized hoteling, offering clients greater control.
  • Facility Design: New, flexible build, amenable to advancements in manufacturing technology and not saddled with legacy infrastructure designed for pharmaceutical products.
  • McMaster Innovation Park Campus: Will include integrated services, suppliers and incubators; a nucleus of synergies and opportunities for clients.
  • Next Generation Technologies: Fully closed platforms for culture intensification and reduction in cost of goods sold.